TNF and Crohn disease: This would allow one of the limitations of the current network at the present time to be overcome with regard to the effects of Ustekinumab, a monoclonal antibody targeting free IL12 and IL23, which has been recently approved for moderately to severely active Crohn’s disease in adults who have failed to treatment with immunomodulators, or more than one TNFα blocker [80].